{"id":"https://openalex.org/W2148375003","doi":"https://doi.org/10.1158/1535-7163.mct-10-0299","title":"Phase I Study of the Selective Aurora A Kinase Inhibitor MLN8054 in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Pharmacodynamics","display_name":"Phase I Study of the Selective Aurora A Kinase Inhibitor MLN8054 in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Pharmacodynamics","alternate_titles":[],"publication_year":2010,"publication_date":"2010-10-01","ids":{"openalex":"https://openalex.org/W2148375003","doi":"https://doi.org/10.1158/1535-7163.mct-10-0299","mag":"2148375003","pmid":"https://pubmed.ncbi.nlm.nih.gov/20724522"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.mct-10-0299","doi":"https://doi.org/10.1158/1535-7163.mct-10-0299","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-10-0299","pdf_url":"https://aacrjournals.org/mct/article-pdf/9/10/2844/2330946/2844.pdf","source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2148375003"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://aacrjournals.org/mct/article-pdf/9/10/2844/2330946/2844.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5082191671","display_name":"Teresa Mercade Macarulla","orcid":"https://orcid.org/0000-0002-5856-4082","observed_orcids":["https://orcid.org/0000-0002-5856-4082","https://orcid.org/0000-0002-1881-362X"]},"institutions":[{"id":"https://openalex.org/I123044942","display_name":"Universitat Aut\u00f2noma de Barcelona","ror":"https://ror.org/052g8jq94","country_code":"ES","type":"education","lineage":["https://openalex.org/I123044942"]},{"id":"https://openalex.org/I16097986","display_name":"Universitat de Val\u00e8ncia","ror":"https://ror.org/043nxc105","country_code":"ES","type":"education","lineage":["https://openalex.org/I16097986"]}],"countries":["ES"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Teresa Macarulla","raw_affiliation_strings":["Authors' Affiliations:\u20081Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; 2Hospital Cl\u00ednico, University of Valencia, Valencia, Spain; and 3Millennium Pharmaceuticals Inc., Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; 2Hospital Cl\u00ednico, University of Valencia, Valencia, Spain; and 3Millennium Pharmaceuticals Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I123044942","https://openalex.org/I16097986"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091727687","display_name":"Andr\u00e8s M.R. Cervantes","orcid":"https://orcid.org/0000-0003-3806-3691","observed_orcids":["https://orcid.org/0000-0003-3806-3691"]},"institutions":[{"id":"https://openalex.org/I123044942","display_name":"Universitat Aut\u00f2noma de Barcelona","ror":"https://ror.org/052g8jq94","country_code":"ES","type":"education","lineage":["https://openalex.org/I123044942"]},{"id":"https://openalex.org/I16097986","display_name":"Universitat de Val\u00e8ncia","ror":"https://ror.org/043nxc105","country_code":"ES","type":"education","lineage":["https://openalex.org/I16097986"]}],"countries":["ES"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Andres Cervantes","raw_affiliation_strings":["Authors' Affiliations:\u20081Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; 2Hospital Cl\u00ednico, University of Valencia, Valencia, Spain; and 3Millennium Pharmaceuticals Inc., Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; 2Hospital Cl\u00ednico, University of Valencia, Valencia, Spain; and 3Millennium Pharmaceuticals Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I123044942","https://openalex.org/I16097986"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030657436","display_name":"Elena \u00c9lez","orcid":"https://orcid.org/0000-0002-4653-6324","observed_orcids":["https://orcid.org/0000-0002-4653-6324"]},"institutions":[{"id":"https://openalex.org/I123044942","display_name":"Universitat Aut\u00f2noma de Barcelona","ror":"https://ror.org/052g8jq94","country_code":"ES","type":"education","lineage":["https://openalex.org/I123044942"]},{"id":"https://openalex.org/I16097986","display_name":"Universitat de Val\u00e8ncia","ror":"https://ror.org/043nxc105","country_code":"ES","type":"education","lineage":["https://openalex.org/I16097986"]}],"countries":["ES"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Elena Elez","raw_affiliation_strings":["Authors' Affiliations:\u20081Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; 2Hospital Cl\u00ednico, University of Valencia, Valencia, Spain; and 3Millennium Pharmaceuticals Inc., Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; 2Hospital Cl\u00ednico, University of Valencia, Valencia, Spain; and 3Millennium Pharmaceuticals Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I123044942","https://openalex.org/I16097986"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037247287","display_name":"Edith Rodr\u00edguez-Braun","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I123044942","display_name":"Universitat Aut\u00f2noma de Barcelona","ror":"https://ror.org/052g8jq94","country_code":"ES","type":"education","lineage":["https://openalex.org/I123044942"]},{"id":"https://openalex.org/I16097986","display_name":"Universitat de Val\u00e8ncia","ror":"https://ror.org/043nxc105","country_code":"ES","type":"education","lineage":["https://openalex.org/I16097986"]}],"countries":["ES"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Edith Rodr\u00edguez-Braun","raw_affiliation_strings":["Authors' Affiliations:\u20081Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; 2Hospital Cl\u00ednico, University of Valencia, Valencia, Spain; and 3Millennium Pharmaceuticals Inc., Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; 2Hospital Cl\u00ednico, University of Valencia, Valencia, Spain; and 3Millennium Pharmaceuticals Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I123044942","https://openalex.org/I16097986"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004300577","display_name":"Jose M Baselga","orcid":"https://orcid.org/0000-0003-1361-4063","observed_orcids":["https://orcid.org/0000-0003-1361-4063"]},"institutions":[{"id":"https://openalex.org/I123044942","display_name":"Universitat Aut\u00f2noma de Barcelona","ror":"https://ror.org/052g8jq94","country_code":"ES","type":"education","lineage":["https://openalex.org/I123044942"]},{"id":"https://openalex.org/I16097986","display_name":"Universitat de Val\u00e8ncia","ror":"https://ror.org/043nxc105","country_code":"ES","type":"education","lineage":["https://openalex.org/I16097986"]}],"countries":["ES"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jos\u00e9 Baselga","raw_affiliation_strings":["Authors' Affiliations:\u20081Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; 2Hospital Cl\u00ednico, University of Valencia, Valencia, Spain; and 3Millennium Pharmaceuticals Inc., Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; 2Hospital Cl\u00ednico, University of Valencia, Valencia, Spain; and 3Millennium Pharmaceuticals Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I123044942","https://openalex.org/I16097986"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055862157","display_name":"Susana Rosell\u00f3","orcid":"https://orcid.org/0000-0003-3915-4130","observed_orcids":["https://orcid.org/0000-0003-3915-4130"]},"institutions":[{"id":"https://openalex.org/I123044942","display_name":"Universitat Aut\u00f2noma de Barcelona","ror":"https://ror.org/052g8jq94","country_code":"ES","type":"education","lineage":["https://openalex.org/I123044942"]},{"id":"https://openalex.org/I16097986","display_name":"Universitat de Val\u00e8ncia","ror":"https://ror.org/043nxc105","country_code":"ES","type":"education","lineage":["https://openalex.org/I16097986"]}],"countries":["ES"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Susana Rosell\u00f3","raw_affiliation_strings":["Authors' Affiliations:\u20081Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; 2Hospital Cl\u00ednico, University of Valencia, Valencia, Spain; and 3Millennium Pharmaceuticals Inc., Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; 2Hospital Cl\u00ednico, University of Valencia, Valencia, Spain; and 3Millennium Pharmaceuticals Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I123044942","https://openalex.org/I16097986"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Gemma Sala","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I123044942","display_name":"Universitat Aut\u00f2noma de Barcelona","ror":"https://ror.org/052g8jq94","country_code":"ES","type":"education","lineage":["https://openalex.org/I123044942"]},{"id":"https://openalex.org/I16097986","display_name":"Universitat de Val\u00e8ncia","ror":"https://ror.org/043nxc105","country_code":"ES","type":"education","lineage":["https://openalex.org/I16097986"]}],"countries":["ES"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Gemma Sala","raw_affiliation_strings":["Authors' Affiliations:\u20081Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; 2Hospital Cl\u00ednico, University of Valencia, Valencia, Spain; and 3Millennium Pharmaceuticals Inc., Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; 2Hospital Cl\u00ednico, University of Valencia, Valencia, Spain; and 3Millennium Pharmaceuticals Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I123044942","https://openalex.org/I16097986"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114045814","display_name":"Inma Blasco","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I123044942","display_name":"Universitat Aut\u00f2noma de Barcelona","ror":"https://ror.org/052g8jq94","country_code":"ES","type":"education","lineage":["https://openalex.org/I123044942"]},{"id":"https://openalex.org/I16097986","display_name":"Universitat de Val\u00e8ncia","ror":"https://ror.org/043nxc105","country_code":"ES","type":"education","lineage":["https://openalex.org/I16097986"]}],"countries":["ES"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Inma Blasco","raw_affiliation_strings":["Authors' Affiliations:\u20081Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; 2Hospital Cl\u00ednico, University of Valencia, Valencia, Spain; and 3Millennium Pharmaceuticals Inc., Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; 2Hospital Cl\u00ednico, University of Valencia, Valencia, Spain; and 3Millennium Pharmaceuticals Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I123044942","https://openalex.org/I16097986"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026551753","display_name":"Hadi Danaee","orcid":"https://orcid.org/0000-0003-1225-1301","observed_orcids":["https://orcid.org/0000-0003-1225-1301"]},"institutions":[{"id":"https://openalex.org/I123044942","display_name":"Universitat Aut\u00f2noma de Barcelona","ror":"https://ror.org/052g8jq94","country_code":"ES","type":"education","lineage":["https://openalex.org/I123044942"]},{"id":"https://openalex.org/I16097986","display_name":"Universitat de Val\u00e8ncia","ror":"https://ror.org/043nxc105","country_code":"ES","type":"education","lineage":["https://openalex.org/I16097986"]}],"countries":["ES"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Hadi Danaee","raw_affiliation_strings":["Authors' Affiliations:\u20081Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; 2Hospital Cl\u00ednico, University of Valencia, Valencia, Spain; and 3Millennium Pharmaceuticals Inc., Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; 2Hospital Cl\u00ednico, University of Valencia, Valencia, Spain; and 3Millennium Pharmaceuticals Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I123044942","https://openalex.org/I16097986"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002429045","display_name":"Yih Lee","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I123044942","display_name":"Universitat Aut\u00f2noma de Barcelona","ror":"https://ror.org/052g8jq94","country_code":"ES","type":"education","lineage":["https://openalex.org/I123044942"]},{"id":"https://openalex.org/I16097986","display_name":"Universitat de Val\u00e8ncia","ror":"https://ror.org/043nxc105","country_code":"ES","type":"education","lineage":["https://openalex.org/I16097986"]}],"countries":["ES"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Yih Lee","raw_affiliation_strings":["Authors' Affiliations:\u20081Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; 2Hospital Cl\u00ednico, University of Valencia, Valencia, Spain; and 3Millennium Pharmaceuticals Inc., Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; 2Hospital Cl\u00ednico, University of Valencia, Valencia, Spain; and 3Millennium Pharmaceuticals Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I123044942","https://openalex.org/I16097986"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109218450","display_name":"Jeffrey Ecsedy","orcid":"https://orcid.org/0000-0002-4232-5490","observed_orcids":["https://orcid.org/0000-0002-4232-5490"]},"institutions":[{"id":"https://openalex.org/I123044942","display_name":"Universitat Aut\u00f2noma de Barcelona","ror":"https://ror.org/052g8jq94","country_code":"ES","type":"education","lineage":["https://openalex.org/I123044942"]},{"id":"https://openalex.org/I16097986","display_name":"Universitat de Val\u00e8ncia","ror":"https://ror.org/043nxc105","country_code":"ES","type":"education","lineage":["https://openalex.org/I16097986"]}],"countries":["ES"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jeffrey Ecsedy","raw_affiliation_strings":["Authors' Affiliations:\u20081Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; 2Hospital Cl\u00ednico, University of Valencia, Valencia, Spain; and 3Millennium Pharmaceuticals Inc., Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; 2Hospital Cl\u00ednico, University of Valencia, Valencia, Spain; and 3Millennium Pharmaceuticals Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I123044942","https://openalex.org/I16097986"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027501007","display_name":"Vaishali Shinde","orcid":"https://orcid.org/0000-0001-5075-9283","observed_orcids":["https://orcid.org/0000-0001-5075-9283"]},"institutions":[{"id":"https://openalex.org/I123044942","display_name":"Universitat Aut\u00f2noma de Barcelona","ror":"https://ror.org/052g8jq94","country_code":"ES","type":"education","lineage":["https://openalex.org/I123044942"]},{"id":"https://openalex.org/I16097986","display_name":"Universitat de Val\u00e8ncia","ror":"https://ror.org/043nxc105","country_code":"ES","type":"education","lineage":["https://openalex.org/I16097986"]}],"countries":["ES"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Vaishali Shinde","raw_affiliation_strings":["Authors' Affiliations:\u20081Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; 2Hospital Cl\u00ednico, University of Valencia, Valencia, Spain; and 3Millennium Pharmaceuticals Inc., Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; 2Hospital Cl\u00ednico, University of Valencia, Valencia, Spain; and 3Millennium Pharmaceuticals Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I123044942","https://openalex.org/I16097986"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003610011","display_name":"Arijit Chakravarty","orcid":"https://orcid.org/0000-0003-1338-5432","observed_orcids":["https://orcid.org/0000-0003-1338-5432"]},"institutions":[{"id":"https://openalex.org/I123044942","display_name":"Universitat Aut\u00f2noma de Barcelona","ror":"https://ror.org/052g8jq94","country_code":"ES","type":"education","lineage":["https://openalex.org/I123044942"]},{"id":"https://openalex.org/I16097986","display_name":"Universitat de Val\u00e8ncia","ror":"https://ror.org/043nxc105","country_code":"ES","type":"education","lineage":["https://openalex.org/I16097986"]}],"countries":["ES"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Arijit Chakravarty","raw_affiliation_strings":["Authors' Affiliations:\u20081Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; 2Hospital Cl\u00ednico, University of Valencia, Valencia, Spain; and 3Millennium Pharmaceuticals Inc., Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; 2Hospital Cl\u00ednico, University of Valencia, Valencia, Spain; and 3Millennium Pharmaceuticals Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I123044942","https://openalex.org/I16097986"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090670345","display_name":"Douglas Bowman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I123044942","display_name":"Universitat Aut\u00f2noma de Barcelona","ror":"https://ror.org/052g8jq94","country_code":"ES","type":"education","lineage":["https://openalex.org/I123044942"]},{"id":"https://openalex.org/I16097986","display_name":"Universitat de Val\u00e8ncia","ror":"https://ror.org/043nxc105","country_code":"ES","type":"education","lineage":["https://openalex.org/I16097986"]}],"countries":["ES"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Douglas Bowman","raw_affiliation_strings":["Authors' Affiliations:\u20081Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; 2Hospital Cl\u00ednico, University of Valencia, Valencia, Spain; and 3Millennium Pharmaceuticals Inc., Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; 2Hospital Cl\u00ednico, University of Valencia, Valencia, Spain; and 3Millennium Pharmaceuticals Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I123044942","https://openalex.org/I16097986"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100321336","display_name":"Hua Liu","orcid":"https://orcid.org/0000-0003-2798-3337","observed_orcids":["https://orcid.org/0000-0003-2798-3337","https://orcid.org/0009-0007-8715-2988"]},"institutions":[{"id":"https://openalex.org/I123044942","display_name":"Universitat Aut\u00f2noma de Barcelona","ror":"https://ror.org/052g8jq94","country_code":"ES","type":"education","lineage":["https://openalex.org/I123044942"]},{"id":"https://openalex.org/I16097986","display_name":"Universitat de Val\u00e8ncia","ror":"https://ror.org/043nxc105","country_code":"ES","type":"education","lineage":["https://openalex.org/I16097986"]}],"countries":["ES"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Hua Liu","raw_affiliation_strings":["Authors' Affiliations:\u20081Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; 2Hospital Cl\u00ednico, University of Valencia, Valencia, Spain; and 3Millennium Pharmaceuticals Inc., Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; 2Hospital Cl\u00ednico, University of Valencia, Valencia, Spain; and 3Millennium Pharmaceuticals Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I123044942","https://openalex.org/I16097986"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087385450","display_name":"Omar E. Eton","orcid":"https://orcid.org/0000-0002-9141-553X","observed_orcids":["https://orcid.org/0000-0002-9141-553X"]},"institutions":[{"id":"https://openalex.org/I123044942","display_name":"Universitat Aut\u00f2noma de Barcelona","ror":"https://ror.org/052g8jq94","country_code":"ES","type":"education","lineage":["https://openalex.org/I123044942"]},{"id":"https://openalex.org/I16097986","display_name":"Universitat de Val\u00e8ncia","ror":"https://ror.org/043nxc105","country_code":"ES","type":"education","lineage":["https://openalex.org/I16097986"]}],"countries":["ES"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Omar Eton","raw_affiliation_strings":["Authors' Affiliations:\u20081Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; 2Hospital Cl\u00ednico, University of Valencia, Valencia, Spain; and 3Millennium Pharmaceuticals Inc., Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; 2Hospital Cl\u00ednico, University of Valencia, Valencia, Spain; and 3Millennium Pharmaceuticals Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I123044942","https://openalex.org/I16097986"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069781389","display_name":"Howard J. Fingert","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I123044942","display_name":"Universitat Aut\u00f2noma de Barcelona","ror":"https://ror.org/052g8jq94","country_code":"ES","type":"education","lineage":["https://openalex.org/I123044942"]},{"id":"https://openalex.org/I16097986","display_name":"Universitat de Val\u00e8ncia","ror":"https://ror.org/043nxc105","country_code":"ES","type":"education","lineage":["https://openalex.org/I16097986"]}],"countries":["ES"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Howard Fingert","raw_affiliation_strings":["Authors' Affiliations:\u20081Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; 2Hospital Cl\u00ednico, University of Valencia, Valencia, Spain; and 3Millennium Pharmaceuticals Inc., Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; 2Hospital Cl\u00ednico, University of Valencia, Valencia, Spain; and 3Millennium Pharmaceuticals Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I123044942","https://openalex.org/I16097986"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5015190461","display_name":"Josep M. Tabernero","orcid":"https://orcid.org/0000-0002-2495-8139","observed_orcids":["https://orcid.org/0000-0002-2495-8139"]},"institutions":[{"id":"https://openalex.org/I123044942","display_name":"Universitat Aut\u00f2noma de Barcelona","ror":"https://ror.org/052g8jq94","country_code":"ES","type":"education","lineage":["https://openalex.org/I123044942"]},{"id":"https://openalex.org/I16097986","display_name":"Universitat de Val\u00e8ncia","ror":"https://ror.org/043nxc105","country_code":"ES","type":"education","lineage":["https://openalex.org/I16097986"]}],"countries":["ES"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Josep Tabernero","raw_affiliation_strings":["Authors' Affiliations:\u20081Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; 2Hospital Cl\u00ednico, University of Valencia, Valencia, Spain; and 3Millennium Pharmaceuticals Inc., Cambridge, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Vall d'Hebron University Hospital, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain; 2Hospital Cl\u00ednico, University of Valencia, Valencia, Spain; and 3Millennium Pharmaceuticals Inc., Cambridge, Massachusetts","institution_ids":["https://openalex.org/I123044942","https://openalex.org/I16097986"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5015190461"],"corresponding_institution_ids":["https://openalex.org/I123044942","https://openalex.org/I16097986"],"apc_list":null,"apc_paid":null,"fwci":3.2525,"has_fulltext":true,"cited_by_count":96,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.92621345,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":100},"biblio":{"volume":"9","issue":"10","first_page":"2844","last_page":"2852"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10492","display_name":"Microtubule and mitosis dynamics","score":0.9696999788284302,"subfield":{"id":"https://openalex.org/subfields/1307","display_name":"Cell Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10492","display_name":"Microtubule and mitosis dynamics","score":0.9696999788284302,"subfield":{"id":"https://openalex.org/subfields/1307","display_name":"Cell Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.010200000368058681,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10274","display_name":"Heterocyclic Compound Synthesis and Bioactivity","score":0.0017000000225380063,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mln8054","display_name":"MLN8054","score":0.9980000257492065},{"id":"https://openalex.org/keywords/aurora-a-kinase-inhibitor","display_name":"Aurora A kinase inhibitor","score":0.8399999737739563},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.859000027179718},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.9739999771118164},{"id":"https://openalex.org/keywords/sleepiness","display_name":"sleepiness","score":0.9599999785423279},{"id":"https://openalex.org/keywords/elevated-liver-enzymes","display_name":"elevated liver enzymes","score":0.9610000252723694},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9589999914169312},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9800000190734863},{"id":"https://openalex.org/keywords/mitotic-index","display_name":"mitotic index","score":0.9580000042915344},{"id":"https://openalex.org/keywords/spindle-bipolarity","display_name":"spindle bipolarity","score":0.7879999876022339},{"id":"https://openalex.org/keywords/oral-mucositis","display_name":"oral mucositis","score":0.7570000290870667},{"id":"https://openalex.org/keywords/dosing-regimen","display_name":"dosing regimen","score":0.6499999761581421},{"id":"https://openalex.org/keywords/mln8237","display_name":"MLN8237","score":0.8510000109672546}],"concepts":[{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.8255747556686401},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7305392026901245},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6568756103515625},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6238254308700562},{"id":"https://openalex.org/C2778496288","wikidata":"https://www.wikidata.org/wiki/Q6931269","display_name":"Mucositis","level":3,"score":0.5777007937431335},{"id":"https://openalex.org/C2779034229","wikidata":"https://www.wikidata.org/wiki/Q1077823","display_name":"Somnolence","level":3,"score":0.565363883972168},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.4903240501880646},{"id":"https://openalex.org/C20552341","wikidata":"https://www.wikidata.org/wiki/Q4822632","display_name":"Aurora inhibitor","level":4,"score":0.45272448658943176},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.4500206410884857},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4297231137752533},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.42621779441833496},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2687809467315674},{"id":"https://openalex.org/C29537977","wikidata":"https://www.wikidata.org/wiki/Q188941","display_name":"Cell cycle","level":3,"score":0.13414603471755981}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001552","descriptor_name":"Benzazepines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D001552","descriptor_name":"Benzazepines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D001552","descriptor_name":"Benzazepines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":false},{"descriptor_ui":"D017346","descriptor_name":"Protein Serine-Threonine Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D020714","descriptor_name":"Maximum Tolerated Dose","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D064127","descriptor_name":"Aurora Kinases","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1158/1535-7163.mct-10-0299","doi":"https://doi.org/10.1158/1535-7163.mct-10-0299","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-10-0299","pdf_url":"https://aacrjournals.org/mct/article-pdf/9/10/2844/2330946/2844.pdf","source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},{"id":"pmid:20724522","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20724522","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular cancer therapeutics","raw_type":"Clinical Trial, Phase I"}],"best_oa_location":{"id":"doi:10.1158/1535-7163.mct-10-0299","doi":"https://doi.org/10.1158/1535-7163.mct-10-0299","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-10-0299","pdf_url":"https://aacrjournals.org/mct/article-pdf/9/10/2844/2330946/2844.pdf","source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2148375003.pdf","grobid_xml":"https://content.openalex.org/works/W2148375003.grobid-xml"},"referenced_works_count":20,"referenced_works":["https://openalex.org/W1479400057","https://openalex.org/W1556655356","https://openalex.org/W1970675560","https://openalex.org/W1979849831","https://openalex.org/W2012618476","https://openalex.org/W2031901100","https://openalex.org/W2035179505","https://openalex.org/W2052672292","https://openalex.org/W2060747696","https://openalex.org/W2064261028","https://openalex.org/W2098517908","https://openalex.org/W2116565287","https://openalex.org/W2121169754","https://openalex.org/W2122742535","https://openalex.org/W2126005827","https://openalex.org/W2126572395","https://openalex.org/W2139248078","https://openalex.org/W2160475600","https://openalex.org/W2276451490","https://openalex.org/W2396517119"],"related_works":["https://openalex.org/W2007608739","https://openalex.org/W2753350642","https://openalex.org/W2301709473","https://openalex.org/W2261162547","https://openalex.org/W603747038","https://openalex.org/W7099449396","https://openalex.org/W1982959429","https://openalex.org/W2171919275","https://openalex.org/W2140029079","https://openalex.org/W2278109184"],"abstract_inverted_index":{"This":[0],"phase":[1],"I":[2],"trial":[3],"examined":[4],"the":[5,49,92,127],"safety,":[6],"pharmacokinetics,":[7],"and":[8,51,64,78,137,187,195,217,229],"pharmacodynamics":[9],"of":[10,17,29,42,115,121,132,185,200,226,233],"MLN8054,":[11],"an":[12],"oral,":[13],"selective,":[14,243],"small-molecule":[15],"inhibitor":[16],"Aurora":[18,201,236,245],"A":[19,202,237,240,246],"kinase.":[20],"Patients":[21,68,108],"with":[22,91,104,174],"advanced":[23],"solid":[24],"tumors":[25],"received":[26,112],"increasing":[27],"doses":[28],"MLN8054":[30,168,204],"in":[31,40,45,69,126,211,223,251],"28-day":[32,212],"cycles":[33,213],"until":[34],"dose-limiting":[35],"toxicity":[36],"(DLT)":[37],"was":[38,55,123,161,178,214],"seen":[39,143],"\u22652":[41],"3-6":[43],"patients":[44],"a":[46,113,158],"cohort.":[47,129],"For":[48],"10-mg":[50],"20-mg":[52,128],"cohorts,":[53],"treatment":[54],"administered":[56],"once":[57],"daily":[58,85],"on":[59,86],"days":[60,87,210],"1":[61,88,116],"to":[62,66,89,98,156,180,208],"5":[63],"8":[65],"12.":[67],"later":[70],"cohorts":[71],"(25,":[72],"35,":[73],"45,":[74],"55,":[75],"60,":[76],"70,":[77],"80":[79,146,166],"mg/day)":[80],"were":[81,142,171,219],"treated":[82],"four":[83],"times":[84],"14,":[90],"largest":[93],"dose":[94],"at":[95,144,164],"bedtime":[96],"(QID-14D)":[97],"mitigate":[99],"benzodiazepine-like":[100],"effects":[101],"possibly":[102],"associated":[103],"peak":[105],"plasma":[106],"concentrations.":[107],"(n":[109,134,139,152],"=":[110,135,140,153],"43)":[111],"median":[114],"cycle":[117],"(range,":[118],"1-10).":[119],"DLT":[120],"somnolence":[122,133],"first":[124],"noted":[125],"Two":[130],"DLTs":[131],"1)":[136,141],"transaminitis":[138,218],"QID-14D":[145,165],"mg.":[147,167],"Grade":[148],"2":[149],"oral":[150],"mucositis":[151],"1),":[154],"predicted":[155],"be":[157],"mechanistic":[159],"effect,":[160],"observed":[162],"only":[163],"exposure":[169],"levels":[170],"roughly":[172],"linear":[173],"dose;":[175],"terminal":[176],"half-life":[177],"30":[179],"40":[181],"hours.":[182],"Pharmacodynamic":[183,221],"analyses":[184,222],"skin":[186,228],"tumor":[188,230],"mitotic":[189,191,224],"indices,":[190],"cell":[192],"chromosome":[193],"alignment,":[194],"spindle":[196],"bipolarity":[197],"provided":[198,231],"evidence":[199],"inhibition.":[203,239],"dosing":[205],"for":[206,235],"10":[207],"14":[209],"feasible.":[215],"Somnolence":[216],"DLTs.":[220],"cells":[225],"both":[227],"proof":[232],"mechanism":[234],"kinase":[238,247],"more":[241],"potent,":[242],"second-generation":[244],"inhibitor,":[248],"MLN8237,":[249],"is":[250],"clinical":[252],"development.":[253]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2148375003","counts_by_year":[{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":3},{"year":2021,"cited_by_count":8},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":7},{"year":2015,"cited_by_count":12},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":17},{"year":2012,"cited_by_count":16}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
